Upgrade to SI Premium - Free Trial

Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval

June 12, 2024 7:45 AM
Oppenheimer upped their price target on Moderna (NASDAQ: MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change Hot List

Next Articles